Measuring ACPA in the general population or primary care: is it useful?

Rheumatoid arthritis (RA) is associated with a significant disease burden and high costs for society. Because the disease has identifiable preclinical stages, screening and prevention have become a possibility in RA. Anticitrullinated peptide antibodies (ACPAs) are arguably the most likely candidate...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatic & musculoskeletal diseases open 2020-02, Vol.6 (1), p.e001085
Main Authors: Finckh, Axel, Courvoisier, Delphine, Lamacchia, Celine, Studer, O., Trunk, E., Gilbert, B.
Format: Article
Language:English
Subjects:
Anti-CCP
Anti-Citrullinated Protein Antibodies - blood
Arthritis, Rheumatoid - diagnosis
Arthritis, Rheumatoid - economics
Arthritis, Rheumatoid - epidemiology
Arthritis, Rheumatoid - immunology
autoantibodies
Autoantibodies - immunology
Biomarkers - analysis
Cost of Illness
Disease
Disease prevention
health services research
Humans
Immunoglobulins
Intervention
Male
Mass Screening - methods
Pathogenesis
Peptides
Predictive Value of Tests
Prevalence
Primary care
Primary Health Care
Proteins
Rheumatoid Arthritis
Risk Assessment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rheumatoid arthritis (RA) is associated with a significant disease burden and high costs for society. Because the disease has identifiable preclinical stages, screening and prevention have become a possibility in RA. Anticitrullinated peptide antibodies (ACPAs) are arguably the most likely candidate biomarker to screen for RA. This paper reviews the evidence for the use of ACPAs as a screening test in the broader general population, to identify individuals at high risk of subsequent onset of RA. We will review the diagnostic properties of the test and its positive and negative predictive value in different settings. We will discuss how ACPA testing could effectively be integrated in a broader screening strategy for RA.
ISSN:2056-5933
2056-5933
DOI:10.1136/rmdopen-2019-001085